Eribulin in the treatment of advanced breast cancer: real-world scenario from 39 Italian centers

Eribulin in the treatment of advanced breast cancer: real-world scenario from 39 Italian centers – ESEMPiO study

Published:2019-01 Issue:1 Volume:15 Page:33-44
ISSN:1479-6694
Container-title:Future Oncology
language:en
Short-container-title:Future Oncology

Author:

Barni Sandro¹,Livraghi Luca²,Morritti Maria³,Vici Patrizia⁴,Michelotti Andrea⁵,Cinieri Saverio⁶,Fontanella Caterina⁷,Porcu Luca⁸,Del Mastro Lucia⁹,Puglisi Fabio⁷¹⁰,

Affiliation:

1. Oncology Unit, Medical Department, ASST Bergamo Ovest, 24047, Treviglio, Italy

2. Medical Oncology Unit, ASST Papa Giovanni XXIII, 24127, Bergamo, Italy

3. Oncology Unit, Ospedale Casa Sollievo della Sofferenza, 71013, San Giovanni Rotondo, Foggia, Italy

4. Division of Medical Oncology 2, “Regina Elena” National Cancer Institute, 00128, Rome, Italy

5. Oncology Unit 1, Azienda Ospedaliera Universitaria Pisana, 56126, Pisa, Italy

6. Medical Oncology Division and Breast Unit, “Senatore Antonio Perrino” Hospital, 72100, Brindisi, Italy

7. Unit of Medical Oncology and Cancer Prevention, IRCCS Centro di Riferimento Oncologico Aviano-National Cancer Institute, 33081, Aviano, Italy

8. Laboratory of Methodology for Clinical Research, Oncology Department, IRCCS – Istituto di Ricerche Farmacologiche Mario Negri, 20156, Milan, Italy

9. Department of Internal Medicine, University of Genova, Ospedale Policlinico San Martino, 16132, Genoa, Italy

10. Medical Oncology, Department of Medicine, University of Udine, 33100, Udine, Italy

Abstract

Aim: We performed a multicenter retrospective cohort study of eribulin mesylate (EM) use in Italy, to describe the current practice for metastatic breast cancer patients (ESEMPiO) in the real-world. Patients & methods: Baseline characteristics, treatment administration and safety were summarized using descriptive statistics. Results: No safety concerns were raised in the population enrolled in the ESEMPiO database and treated in a real-life practice. Median progression-free survival and overall survival were 3.2 and 10.1 months, respectively. EM activity was similar between breast cancer subtypes. Conclusion: In metastatic breast cancer patients treated with EM in ‘real-world’ setting, the clinician-registered outcomes were comparable to those reported in pivotal trials. Furthermore, EM maintained clinical activity and a tolerable safety profile.

Publisher

Future Medicine Ltd

Subject

Cancer Research,Oncology,General Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/fon-2018-0324

Reference18 articles.

1. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

2. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth

3. Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase

4. Comparison of the Activities of the Truncated Halichondrin B Analog NSC 707389 (E7389) with Those of the Parent Compound and a Proposed Binding Site on Tubulin

5. Induction of Morphological and Biochemical Apoptosis following Prolonged Mitotic Blockage by Halichondrin B Macrocyclic Ketone Analog E7389

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Feasibility and tolerability of eribulin-based chemotherapy versus other chemotherapy regimens for patients with metastatic triple-negative breast cancer: a single-centre retrospective study;Frontiers in Cell and Developmental Biology;2024-02-22

2. A phase Ib/II study of eribulin in combination with cyclophosphamide in patients with advanced breast cancer;Breast Cancer Research and Treatment;2023-10-10

3. Effectiveness, safety, and impact on quality of life of eribulin‐based therapy in heavily pretreated patients with metastatic breast cancer: A real‐world analysis;Cancer Medicine;2023-07-05

4. Trastuzumab Deruxtecan for Treating HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies: An Evidence Review Group Perspective of a NICE Single Technology Appraisal;PharmacoEconomics - Open;2023-04-21

5. Recent Advancement in Anticancer Compounds from Marine Organisms: Approval, Use and Bioinformatic Approaches to Predict New Targets;Marine Drugs;2022-12-28